Cybin Inc.

Equities

CLXPF

CA23256X4075

Market Closed - Nyse Other stock markets 04:00:00 2025-01-16 pm EST			5-day change	1st Jan Change
8.930 ^USD	-3.15%		-6.59%	+1.25%

Jan. 15	Cybin, Segal Trials Collaborate to Advance Major Depressive Disorder Treatment	MT
Jan. 15	Cybin Launches Strategic Clinical Site Partnerships to Support Paradigm, A Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder	CI

Cybin Inc. - Special Call

October 08, 2024 at 03:00 pm EDT

Presenter Speech
Robert Sassoon (Analysts)

Fireside chat. Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental health care by developing novel next-generation

This article is reserved for subscribers

To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Cybin Inc.

Cybin, Segal Trials Collaborate to Advance Major Depressive Disorder Treatment	Jan. 15	MT
Cybin Launches Strategic Clinical Site Partnerships to Support Paradigm, A Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder	Jan. 15	CI
Cybin Inc. - Special Call	Dec. 11
Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year	Nov. 18	MT
Cybin Inc. - Special Call	Nov. 18
Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder	Nov. 18	CI
Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	Nov. 13	CI
Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results	Nov. 13	CI
Cybin Inc. - Special Call	24-10-08
Cybin Inc. Announces Executive Appointments	24-10-01	CI
Cybin Inc.(NYSEAM:CYBN) added to S&P Global BMI Index	24-09-22	CI
Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones	24-09-20	CI
Cybin Inc. - Shareholder/Analyst Call	24-08-27
Cybin to Begin Phase 3 Trial of Treatment for Major Depressive Disorder This Summer	24-08-13	MT
Cybin Inc. Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder	24-08-13	CI
Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee	24-08-13	CI
Cybin Inc. Reports Earnings Results for the First Quarter Ended June 30, 2024	24-08-08	CI
Cybin Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	24-06-26	CI
Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development	24-06-11	CI
Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	24-05-06	CI
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	24-04-17	MT
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	24-04-16	MT
Cybin Inc. announced that it has received $150 million in funding from a group of investors	24-03-18	CI
Sector Update: Health Care Stocks Softer Friday Afternoon	24-03-15	MT
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder	24-03-15	MT